Appointment of CFO and Head of Clinical Operations

RNS Number : 3009U

Evgen Pharma PLC

17 January 2017

 

For immediate release

17 January 2017

 

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

 Appointment of CFO and Head of Clinical Operations

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the appointment of Richard Moulson, an experienced healthcare executive, as the Company's Chief Financial Officer ("CFO").

Richard joins Evgen Pharma today as CFO designate for a handover period to 28 February 2017, on which date John Bradshaw, the current CFO, will leave the Company to focus on his work with a new healthcare investment vehicle.

Richard will join the Company's Board and become CFO on 1 March 2017.

Richard graduated in zoology at Exeter University before qualifying as an accountant at Coopers & Lybrand.  He worked in corporate finance at Deutsche Morgan Grenfell for 10 years before working in financial and company secretarial roles at a number of UK biotechnology and technology companies.  Since 2012, Richard has had a portfolio of interests, including recently as CFO of Cogent Breeding Limited and previously as Interim CFO of ReNeuron Group plc and Interim CFO of Enigma Diagnostics Limited.

The Company also announces that David Howat, who holds the non-Board position of Chief Development Officer, will leave Evgen Pharma at the end of March 2017. David led the preclinical and early-stage clinical development of the Company's lead product (SFX-01) through to the Phase II trials.  The Phase II trials will continue to be managed by Dave Chadwick, the Company's Senior Clinical Study Manager, who, on 1 March 2017, assumes the role of Head of Clinical Operations, a non-Board position.

Dr Stephen Franklin, CEO of Evgen Pharma, commented: "On behalf of the Board, I would like to express our sincere thanks to John Bradshaw for his valuable contribution to the development of Evgen Pharma, including his important role in the Company's IPO.  We wish him well for the future".

"I would like to welcome Richard Moulson to Evgen Pharma.  Richard is an experienced CFO with a track record in life sciences and we all look forward to his input to the Company and to the Board".

"Finally, I would like to thank David Howat for being a tremendous asset to Evgen Pharma during our formative years and for helping take our lead product through to the current patient trials, which are managed by our clinical team. David leaves us to join an earlier-stage company and the Board extends its thanks and wishes him every success in his new role."

Further information on Richard Moulson

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Richard Anthony Moulson, age 55 years, has been a director of the following companies during the five years preceding the date of this announcement:

Past directorships

Accelerated Genetics UK Limited

BHFCO Limited

Cogent Breeding Limited

Cogent Canada Corp.

Cogent Holdings Inc.

Dairy Daughters Limited

Five Star Breeders Ltd

Grosvenor Garden Centre Limited

Select Sires UK Limited

STE (Clean Recycling and Energy) Plc

Sterecycle (Cardiff) Ltd

Sterecycle (Harlow) Ltd

Sterecycle (Rotherham) Ltd

Sterecycle (South London) Ltd

Sterecycle Holdings Ltd

Sterecycle Management Services Ltd

World Wide Sires UK Limited

Further disclosures

In September 2012, the following companies, of which Mr. Moulson was a director, were placed into administration; Sterecycle (Rotherham) Ltd ("SRL"), Sterecycle Holdings Ltd, Sterecycle Management Services Ltd and STE (Clean Recycling and Energy) Plc ("STE").  Sterecycle (Cardiff) Ltd was placed into administration in November 2012.  Creditors for STE totalled £1.175m and the dividend paid to creditors was 19.26p in the £.  Creditors for SRL totalled £4.3m and the dividend paid to creditors was 42p in the £.

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes and Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information please visit: www.evgen.com

For a recent analyst research note on Evgen Pharma, please visit:

http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf

 

END

 

 

MSCDBGDBCSBBGRL